Young‐Hyuck Im

Active 1999–2025

Also published as: Young Hyuck Im · Young-Hyuck Im

93: Papers
20,983: Citations
60: h-index
93: i10-index

Citations

Citation sources

Countries

0%22.2%Other 26.8%

Institutions

Fields

Topics

All papers

Sort

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Authors: Jennifer K. Litton, Hope S. Rugo, Johannes Ettl, Sara A. Hurvitz, Anthony Gonçalvès, Kyung-Hun Lee, Louis Fehrenbacher, Rinat Yerushalmi, Lida A. Mina, Miguel Martín, Henri Roché, Young‐Hyuck Im, Ruben G.W. Quek, Denka Markova, Iulia Cristina Tudor, Alison L. Hannah, W. Eiermann, Joanne L. Blum - New England Journal of Medicine 2018 cited by 2,151
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
Authors: Norikazu Masuda, Soo-Jung Lee, Shoichiro Ohtani, Young‐Hyuck Im, Eun Sook Lee, Isao Yokota, Katsumasa Kuroi, Seock‐Ah Im, Byeong‐Woo Park, Sung‐Bae Kim, Yasuhiro Yanagita, Shinji Ohno, Shintaro Takao, Kenjiro Aogi, Hiroji Iwata, Joon Jeong, Aeree Kim, Kyong Hwa Park, Hironobu Sasano, Yasuo Ohashi, Masakazu Toi - New England Journal of Medicine 2017 cited by 1,887
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
Authors: Sandra M. Swain, David Miles, Sung‐Bae Kim, Young‐Hyuck Im, Seock‐Ah Im, Semiglazov Vf, Eva Ciruelos, Andreas Schneeweiß, Sherene Loi, Estefanía Monturus, Emma Clark, Adam Knott, Eleonora Restuccia, Mark Benyunes, Javier Cortés, Richy Agajanian, Rizvana Ahmad, Bahriye Aktas, Victor Hugo Medeiros Alencar, Dino Amadori, Jurandyr Moreira de Andrade, Fábio Franke, Catia Angiolini, Kenjiro Aogi, Jess F. Armor, Wichit Arpornwirat, L. Assersohn, William Audeh, Walter E. Aulitzky, Sérgio Jobim Azevedo, Maria Alejandra Bartoli, Norberto Batista López, María Inés Bianconi, Laura Biganzoli, Ruemu Birhiray, Marianna Bitiņa, Ron Blachy, Kimberly Blackwell, Rita A. Blanchard, Paulette Blanchet, Ion Boiangiu, B. Bower, Christine Brezden‐Masley, Adam Brufsky, Leanne S. Budde, Priscilla B. Caguioa, Lourdes Calvo, Mario Campone, Robert R. Carroll, Hugo R. Castro, Valorie F. Chan, Veena Charu, Saverio Cinieri, Michael Clemens, Emilio Alba Conejo, Eduardo Côrtes, Bruno Coudert, Eduardo Cronemberger, Daniel de Iracema Gomes Cubero, Shaker R. Dakhil, Brooke Daniel, Neville Davidson, Maria de Fátima Dias Gauí, Susana de la Cruz, María del Pilar, G. Delgado, John Ellerton, César Estuardo, Louis Fehrenbacher, Jean-Marc Ferrero, Patrick J. Flynn, Małgorzata Foszczyńska‐Kłoda, Sandra Franco, Hirofumi Fujii, Chris Gallagher, Teresa Gamucci, N Giacomi, Miguel Gil Gil, Antonio González-Martı́n, Vera Gorbunova, E. Gotovkin, Nathan Green, Elza Grincuka, Eva‐Maria Grischke, Vincent Hansen, Jeffrey B. Hargis, Maik Hauschild, Roberto Hegg, Carolyn B. Hendricks, Róbert Hermann, Paulo M. Hoff, Jun Horiguchi, Javier Hornedo Muguiro, Stefano Iacobelli, Kenichi Inoue, Gustavo Ismael, Yoshinori Itoh, Dr Hiroji Iwata, D Jendiroba, Rosa Jochim and 122 more - The Lancet Oncology 2020 cited by 898
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Authors: Luca Gianni, Tadeusz Pieńkowski, Young‐Hyuck Im, Laslo Roman, Ling‐Ming Tseng, Mei-Ching Liu, Aňa Lluch, Elżbieta Starosławska, Juan de la Haba-Rodríguez, Seock‐Ah Im, José Luiz Pedrini, Brigitte Poirier, Paolo Morandi, Semiglazov Vf, Vichien Srimuninnimit, Giulia Bianchi, Tania Szado, Jayantha Ratnayake, Graham Ross, Pinuccia Valagussa - The Lancet Oncology 2011 cited by 2,358
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
Authors: Debu Tripathy, Seock‐Ah Im, Marco Colleoni, Fábio Franke, Aditya Bardia, Nadia Harbeck, Sara A. Hurvitz, Louis W.C. Chow, Joohyuk Sohn, Keun Seok Lee, Saúl Campos-Gómez, Rafael Villanueva-Vázquez, Kyung Hae Jung, Govind Babu, Paul Wheatley‐Price, Michelino De Laurentiis, Young‐Hyuck Im, Sherko Küemmel, Nagi S. El-Saghir, Mei-Ching Liu, Gary P. Carlson, Gareth Hughes, Iván Díaz-Padilla, Caroline Germa, Samit Hirawat, Yen‐Shen Lu - The Lancet Oncology 2018 cited by 1,011
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Authors: José Baselga, Javier Cortés, Sung‐Bae Kim, Seock‐Ah Im, Roberto Hegg, Young‐Hyuck Im, Laslo Roman, José Luiz Pedrini, Tadeusz Pieńkowski, Adam Knott, Emma Clark, Mark Benyunes, Graham Ross, Sandra M. Swain - New England Journal of Medicine 2011 cited by 2,523
Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
Authors: Yen-Shen Lu, Seock-Ah Im, Marco Colleoni, Fabio Franke, Aditya Bardia, Fatima Cardoso, Nadia Harbeck, Sara Hurvitz, Louis Chow, Joohyuk Sohn, Keun Seok Lee, Saul Campos-Gomez, Rafael Villanueva Vazquez, Kyung Hae Jung, K. Govind Babu, Paul Wheatley-Price, Michelino De Laurentiis, Young-Hyuck Im, Sherko Kuemmel, Nagi El-Saghir, Ruth O'Regan, Claudia Gasch, Nadia Solovieff, Craig Wang, Yongyu Wang, Arunava Chakravartty, Yan Ji, Debu Tripathy - Clinical Cancer Research 2021 cited by 263
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
Authors: Luca Gianni, Tadeusz Pieńkowski, Young‐Hyuck Im, Ling‐Ming Tseng, Mei-Ching Liu, Aňa Lluch, Elżbieta Starosławska, Juan de la Haba-Rodríguez, Seock‐Ah Im, José Luiz Pedrini, Brigitte Poirier, Paolo Morandi, Semiglazov Vf, Vichien Srimuninnimit, Giulia Bianchi, Domenico Magazzù, Virginia McNally, Hannah Douthwaite, Graham Ross, Pinuccia Valagussa - The Lancet Oncology 2016 cited by 874
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial
Authors: Jennifer K. Litton, Sara A. Hurvitz, Lida A. Mina, Hope S. Rugo, Ki Hoon Lee, Anthony Gonçalvès, Sami Diab, Natasha Woodward, Annabel Goodwin, Rinat Yerushalmi, Henri Roché, Young‐Hyuck Im, W. Eiermann, Ruben G.W. Quek, Tiziana Usari, Silvana Lanzalone, Akos Czibere, Joanne L. Blum, Miguel Martín, Johannes Ettl - Annals of Oncology 2020 cited by 394
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up
Authors: Martine Piccart, Marion Procter, Debora Fumagalli, Evandro de Azambuja, Emma Clark, Michael S. Ewer, Eleonora Restuccia, Guy Jérusalem, Susan Dent, Linda Reaby, Hervé Bonnefoi, Ian E. Krop, Tsang‐Wu Liu, Tadeusz Pieńkowski, Masakazu Toi, Nicholas Wilcken, Michael Andersson, Young‐Hyuck Im, Ling‐Ming Tseng, Hans-Joachim Lueck, Marco Colleoni, Estefanía Monturus, Mihaela Sicoe, Sébastien Guillaume, José Bines, Richard D. Gelber, Giuseppe Viale, Christoph Thomssen - Journal of Clinical Oncology 2021 cited by 359
Multimodal deep learning models for the prediction of pathologic response to neoadjuvant chemotherapy in breast cancer
Authors: Sunghoon Joo, Eun Sook Ko, Soonhwan Kwon, Eunjoo Jeon, Hyungsik Jung, Ji‐Yeon Kim, Myung Jin Chung, Young‐Hyuck Im - Scientific Reports 2021 cited by 121
Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study
Authors: Edith A. Perez, Carlos H. Barrios, W. Eiermann, Masakazu Toi, Young‐Hyuck Im, PierFranco Conte, Miguel Martín, Tadeusz Pieńkowski, Xavier Pivot, Howard A. Burris, Jennifer Petersen, S Stanzel, Alexander Strasak, Monika Patre, Paul Ellis - Journal of Clinical Oncology 2017 cited by 413
Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial
Authors: Susan Dent, Javier Cortés, Young‐Hyuck Im, Véronique Dièras, Nadia Harbeck, Ian E. Krop, Timothy R. Wilson, Na Cui, Frauke Schimmöller, Jerry Y. Hsu, Jie He, Michelino De Laurentiis, Susana Sousa, Pamela Drullinsky, William Jacot - Annals of Oncology 2020 cited by 163
Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures
Authors: Zhengyan Kan, Ying Ding, Jin-Ho Kim, Hae Hyun Jung, Woosung Chung, Samir Lal, Soonweng Cho, Julio Fernandez-Banet, Se Kyung Lee, Seok Won Kim, Jeong Eon Lee, Yoon‐La Choi, Shibing Deng, Ji‐Yeon Kim, Jin Seok Ahn, Ying Sha, Xinmeng Jasmine Mu, Jae‐Yong Nam, Young‐Hyuck Im, Soo Hyun Lee, Woong‐Yang Park, Seok Jin Nam, Yeon Hee Park - Nature Communications 2018 cited by 210
Prevalence and detection of low-allele-fraction variants in clinical cancer samples
Authors: Hyun‐Tae Shin, Yoon‐La Choi, Jae Won Yun, Nayoung K. D. Kim, Sook‐Young Kim, Hyo Jeong Jeon, Jae‐Yong Nam, Chung Lee, Daeun Ryu, Sang Cheol Kim, Kyunghee Park, Eunjin Lee, Joon Seol Bae, Dae Soon Son, Je‐Gun Joung, Jeeyun Lee, Seung Tae Kim, Myung‐Ju Ahn, Se‐Hoon Lee, Jin Seok Ahn, Woo Yong Lee, Bo Young Oh, Yeon Hee Park, Jeong Eon Lee, Kwang Hyuk Lee, Hee Cheol Kim, Kyoung‐Mee Kim, Young‐Hyuck Im, Keunchil Park, Peter J. Park, Woong‐Yang Park - Nature Communications 2017 cited by 198
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: The Phase III KAITLIN Study
Authors: Ian E. Krop, Seock‐Ah Im, Carlos H. Barrios, Hervé Bonnefoi, Julie R. Gralow, Masakazu Toi, Paul A. Ellis, Luca Gianni, Sandra M. Swain, Young‐Hyuck Im, Michelino De Laurentiis, Zbigniew Nowecki, Chiun‐Sheng Huang, Louis Fehrenbacher, Yoshinori Ito, Jigna Shah, Thomas Boulet, Haiying Liu, Harrison Macharia, Peter C. Trask, Chunyan Song, Eric P. Winer, Nadia Harbeck - Journal of Clinical Oncology 2021 cited by 64
Cytokine profiling in serum-derived exosomes isolated by different methods
Authors: Hae Hyun Jung, Ji‐Yeon Kim, Ji Eun Lim, Young‐Hyuck Im - Scientific Reports 2020 cited by 117
Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE
Authors: Edith A. Perez, Carlos H. Barrios, W. Eiermann, Masakazu Toi, Young‐Hyuck Im, PierFranco Conte, Miguel Martín, Tadeusz Pieńkowski, Xavier Pivot, Howard A. Burris, Jennifer Petersen, Sanne de Haas, Silke Hoersch, Monika Patre, Paul Anthony Ellis - Cancer 2019 cited by 114
Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance
Authors: Hee Kyung Kim, Kyung Hee Park, Youjin Kim, Song Ee Park, Han Sang Lee, Sung Won Lim, Jang Ho Cho, Ji‐Yeon Kim, Jeong Eon Lee, Jin Seok Ahn, Young‐Hyuck Im, Jong Han Yu, Yeon Hee Park - Cancer Research and Treatment 2018 cited by 102
Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer
Authors: Tira J. Tan, Sarah Sammons, Young‐Hyuck Im, Lilin She, Kelly Mundy, Robert Bigelow, Tiffany A. Traina, Carey K. Anders, Joe Yeong, Ezequiel Renzulli, Sung‐Bae Kim, Rebecca Dent - Clinical Cancer Research 2024 cited by 31
Deep Learning-Based Prediction Model for Breast Cancer Recurrence Using Adjuvant Breast Cancer Cohort in Tertiary Cancer Center Registry
Authors: Ji‐Yeon Kim, Yong‐Seok Lee, Jonghan Yu, Youngmin Park, Se Kyung Lee, Minyoung Lee, Jeong Eon Lee, Seok Won Kim, Seok Jin Nam, Yeon Hee Park, Jin Seok Ahn, Mira Kang, Young‐Hyuck Im - Frontiers in Oncology 2021 cited by 44
Impact of chemotherapy-induced alopecia distress on body image, psychosocial well-being, and depression in breast cancer patients
Authors: Eun Kyung Choi, Nayeon Kim, Oliver Chang, Danbee Kang, Seok Jin Nam, Jeong Eon Lee, Se Kyung Lee, Young‐Hyuck Im, Yeon Hee Park, Jung‐Hyun Yang, Juhee Cho - Psycho-Oncology 2014 cited by 225
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial
Authors: Yeon Hee Park, Tae‐Yong Kim, Gun Min Kim, Seok Yun Kang, In Hae Park, Jee Hyun Kim, Kyoung Eun Lee, Hee Kyung Ahn, Moon Hee Lee, Hee‐Jun Kim, Han Jo Kim, Jong In Lee, Su‐Jin Koh, Ji‐Yeon Kim, Kyung-Hun Lee, Joohyuk Sohn, Sung‐Bae Kim, Jin‐Seok Ahn, Young‐Hyuck Im, Kyung Hae Jung, Seock‐Ah Im, HK Ahn, EK Cho, IH Park, KS Lee, S.H. Sim, S-J Hong, Mei‐Hwei Chang, Jae‐Hong Kim, YJ Kim, Sung‐Han Kim, KJ Suh, YH Park, Woong‐Yang Park, Y-L. Choi, JH Yu, Y-H Im, Ahn Js, Jy Hur, So Hyun Park, JY Kim, SJ Nam, JE Lee, SW Kim, Seung‐Koo Lee, S-A. Im, Myung‐Sun Kim, Tae‐Yop Kim, D-Y. Oh, Tae‐Yop Kim, KH Lee, DW Lee, Hyung Jun Kim, Keun‐Hwa Jung, S-B. Kim, J-H Ahn, JE Kim, JH Jung, SY Kang, MS Ahn, YW Choi, GM Kim, JH Sohn, MH Kim, SJ Koh, JK Cheon, JI Lee, ST Lim, SY Hyun, K.S. Lee, Hyung Jun Kim, M. H. Lee, JH Cho, JH Lim - The Lancet Oncology 2019 cited by 130
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial
Authors: Martine Piccart, Eileen Holmes, José Baselga, Evandro de Azambuja, Amylou C. Dueck, Giuseppe Viale, Jo Anne Zujewski, Aron Goldhirsch, Alison Armour, Kathleen I. Pritchard, Ann E. McCullough, Stella Dolci, Eleanor McFadden, Andrew Holmes, Liu Tonghua, Holger Eidtmann, Phuong Dinh, Serena Di Cosimo, Nadia Harbeck, Sergei Tjulandin, Young‐Hyuck Im, Chiun‐Sheng Huang, Véronique Dièras, David W. Hillman, Antonio C. Wolff, Christian Jackisch, István Láng, Michael Untch, Ian Smith, Frances Boyle, Binghe Xu, Henry Gómez, Thomas Suter, Richard D. Gelber, Edith A. Perez - Journal of Clinical Oncology 2015 cited by 374